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Abstract VIP21-caveolin is one of the components which form 
the cytoplasmic surface of caveolae. In vivo, this integral 
membrane protein is found in homo-oligomers with molecular 
masses of approximately 200, 400 and 600 kDa. These oligomers 
are also formed by the addition of eytosol to the in vitro 
synthesized and membrane inserted VIP21-caveolin. Here we 
show that long chain fatty aeyl eoenzyme A esters can completely 
substitute for cytosol in inducing 200 kDa and 400 kDa 
complexes, whereas 25-hydroxy-cbolesterol can produce the 
200 kDa oligomer. In order to understand whether acylation of 
VIP21-eaveolin itself is a prerequisite for oligomerization, we 
studied a mutant protein lacking all three eysteines. When 
analyzed by velocity sucrose gradient centrifugation in the 
presence of the non-ionic detergent oetylglucoside, both palmi- 
toylated and non-palmitoylated VIP21-caveolin formed oligo- 
mers that were indistinguishable. However, only the oligomers of 
the non-palmitoylated protein are disrupted when analyzed by 
SDS-PAGE without boiling. These data suggest hat the protein 
domains of VIP21-eaveolin are the primary determinants of 
oligomerization, hut that palmitoylation of cysteine residues can 
increase the stability of the oligomers. 
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1. Introduction 
The plasma membrane of many mammalian cells contains 
non clathrin coated membrane invaginations, called caveolae 
or plasmalemmal vesicles (reviewed in [1]). The cytoplasmic 
surface of caveolae is covered by multiple filaments wrapped 
around the invaginated plasma membrane [2-5]. In the last 
few years, caveolae have been investigated intensively and 
several possibilities for their function have been suggested. 
These include: alternative endocytic pathway [3,6,7]; transcy- 
tosis [8,9]; receptor-mediated uptake of small molecules (po- 
tocytosis [10,11]); regulation of intracellular calcium concen- 
tration [12,13]; and signal transduction [14-16]. 
VIP21-caveolin, a protein of 21-22 kDa, is so far the best 
biochemical or structural marker for caveolae (for review see 
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[17]). Antibodies against his protein decorate the caveolar 
filaments [5]. VIP21-caveolin is also a constituent of trans- 
Golgi network derived vesicles [18] and is found on the Golgi 
apparatus [19]. 
VIP21-caveolin is an integral membrane protein which has 
an unusual hairpin loop structure in the membrane, xposing 
regions which flank the hydrophobic segment to the cytosol 
[19-21]. The protein has two remarkable and peculiar proper- 
ties which are possibly connected to its function: it is insolu- 
ble in non-ionic detergents such as Triton X-100 or CHAPS 
[15,18] and it can associate with itself to form high molecular 
mass homo-oligomers in vivo as well as in vitro [21,22]. The 
homo-oligomers can be produced from in vitro synthesized 
and membrane inserted VIP21-caveolin by the addition of 
cytosol. This process also requires ATP and GTP. The oligo- 
mers produced in vitro share several properties with those 
isolated from dog lung or from cultivated cells: they are of 
about the same size, are not solubilized by SDS at 25°C and 
are formed in the endoplasmic reticulum (ER) [21]. However, 
in contrast to the oligomers detected in vivo, they do not form 
the Triton insoluble, very high molecular mass complexes. 
The detergent insolubility might correspond to a higher degree 
of 'maturation' of the oligomers. This maturation may be 
acquired at the time the oligomers leave the ER, as they 
pass through the Golgi apparatus or upon their arrival at 
the plasma membrane. 
In this report, we have tried to identify active factor(s) in 
cytosol that are required for the oligomerization of VIP21- 
caveolin. We find that the role of the cytosol is actually to 
stabilize the VIP21-caveolin oligomers (as judged by stability 
in the detergent SDS), and this property depends on palmi- 
toylation of the protein. 
2. Materials and methods 
2.1. Materials 
Detergents were purchased from Calbiochem (San Diego, CA, 
USA); reagents for SDS-PAGE from ICN (Meckenheim, Germany); 
palmitoyl-carnitine and coenzyme A derivatives (lauroyl-, myristoyl-, 
palmitoyl- and stearoyl-CoA) from Sigma (Deisenhofen, Germany). 
Palmitoyl-dethio-CoA was a kind gift from Dr. Theodor Wieland 
(MPI for Medical Research, Heidelberg, Germany). The reagents 
used for cDNA cloning, for in vitro transcription, translation and 
translocation were obtained from the sources described [23]. 
2.2. Cytosol extraction 
Cytosol was prepared from canine brain according to the procedure 
used to prepare cultivated cell cytosol [21]. Before the homogenization 
with a Dounce apparatus, frozen canine brain was cleaned of most of 
its white matter. 
Cytosol was fractionated using a two phase chloroform/methanol/ 
water extraction system as described by Urbani and Simoni [24] and 
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modified as follows. Briefly, 80 ktl of dog brain cytosol, at a concen- 
tration of approximately 35 mg/ml protein, was extracted overnight at 
4°C in a rotating shaker in 1 ml of chloroform/methanol (1/1); an 
equal volume of 0.04 N HC1 was then added. Alternatively, the ex- 
traction was performed with the same volume of chloroform/metha- 
nol/water (1/2/0.25) and followed on the next day by the addition of 
half a volume of chloroform and half a volume of water. After thor- 
ough vortexing, the two phases were separated by centrifugation at 
5000 rpm for 3 min in an Eppendorf centrifuge. The upper aqueous 
phase was removed, concentrated in a rotating evaporator and either 
acetone precipitated (9 volumes acetone for 1 volume aqueous olu- 
tion) or evaporated to dryness. The chloroform phase was carefully 
removed through the protein precipitate present at the interface. Both 
organic phase and interface were dried down. 
The lipid fraction (chloroform phase) was used directly, i.e. the 
post-translational assay was performed in the same tube (see below). 
The interface and aqueous phases were solubilized in the oligomeriza- 
tion buffer (HMKD buffer: 20 mM HEPES pH7.6, 1 mM MgAc, 60 
mM KOAc, 0.2 mM DTT) and stored at -80°C. 
2.3. Post-translational oligomerization assay 
The oligomerization assay was performed after translation of 
VIP21-caveolin i  the presence of dog pancreas microsomes was com- 
pleted [21]. Samples, made up of 3 ~tl of translation products in 5 ~tl 
total volume, were incubated at 30°C for 1 h in the presence of 
HMKD buffer and of various compounds. 
All coenzyme A derivatives were solubilized in HMKD. Palmitic 
acid was solubilized in 100% ethanol and then diluted in HMKD. 
Sphingomyelin and 25-hydroxy-cholesterol were solubilized in chloro- 
form/methanol (1/1), aliquoted to the suitable concentration, and the 
solvent evaporated to dryness. As for the test of lipid fraction, the 
translation mix and buffer were added directly to the dry material and 
pipetted up and down to maximize the lipid 'dispersion'. 
2.4. Construction a d expression of VIP21-caveolin mutants 
The construction and expression in human embryonic kidney 293 
cells of the VIP21-caveolin mutants with all sets of one, two, or all 
three (Cys-) of its cysteine residues changed to serine has already 
been described [20]. In the in vitro oligomerization assay, the trun- 
cated form of Cys- (Tr Cys-) utilizing the Met z2 start codon was 
used, as done previously for the wild-type protein. For this construct, 
the NcoIIXbaI fragment was excised from the pcDNA3 vector and 
cloned in pSP64. The resulting plasmid encodes a form of VIP21- 
caveolin, in which the first 31 amino acids were deleted and the cy- 
steine residues at positions 133, 143 and 156 were changed for serine 
residues. The protein bears a c-myc tag at the carboxy terminus. 
2.5. Analys& of oligomerization products 
The products generated in the post-translational assay were sub- 
jected to SDS-PAGE on a 3-16% gradient gel as previously described 
[21] after solubilization in the usual SDS-gel sample buffer without 
boiling. The possible thioester bonds were released by incubating the 
sample for 20 min at 37°C in the presence of 0.3 M methanolic KOH 
[25]. To 5 ktl of the reaction mix 5 ~tl of 0.6 M methanolic KOH were 
added. The latter was prepared by dilution of a 4 M aqueous olution 
of KOH in absolute methanol. The control sample was incubated in 
the presence of 42.5% methanol alone. 
Quantification of oligomerization was performed by measuring the 
relative radioactivity in various complexes with a phosphoimager 
(BAS2000, FujiX, Japan). Results were expressed as stimulation 
above basal activity after incubation in the presence of the HMKD 
buffer. 
Analysis of VIP21-caveolin oligomers in transfected 293 cells was 
performed using cell lysates solubilized in SDS-PAGE buffer without 
boiling [21]. An alternate assay for the presence of VIP21-caveolin 
oligomers used velocity sucrose gradient centrifugation. Cells were 
lysed on ice in 0.5 ml 60 mM n-octylglucoside/25 mM MES, pH 
6.5/150 mM NaC1 with protease inhibitors; this lysate was overlaid 
onto a 4.2 ml 5-30% sucrose gradient prepared in the same cell lysis 
buffer, centrifuged in an SW55 rotor for 6 h at 53000 rpm 
(340000×g), and 12 equal fractions collected from the top (plus the 
pellet solubilized in gel loading buffer). Samples were analyzed by 
SDS-PAGE (with or without boiling as indicated) and detection uti- 
lized western blotting with monoclonal anti-c-myc antibodies as de- 
scribed [20]. 
3. Results 
3.1. Oligomerization of VIP21-caveolin is stimulated by long 
chain fatty acyl-CoA esters 
We have recently described an in vitro oligomerization as- 
say for VIP21-caveolin. The protein synthesis performed in 
the wheat germ translation system in the presence of dog 
pancreas microsomes i followed by a post-translational ssay 
by incubation the samples at 30°C for 1 h. The major bands 
formed after addition of cytosol (but not in its absence) are a 
doublet of about 200 kDa and a 400 kDa complex, as de- 
tected by SDS-PAGE after treatment of samples at 25°C. We 
used a truncated form of VIP21-caveolin (TR VIP), which co- 
migrates with the smaller isoform of the protein [26] and is 
more effective in forming oligomers [21]. 
Our aim was to seek the active component(s) of cytosol 
involved in the oligomerization of VIP21-caveolin. Previous 
results have shown that the VIP21-caveolin complexes isolated 
in vivo contained not only the protein monomers but also 
glycosphingolipids and cholesterol [27,28]. In our initial ex- 
periments, therefore, we subjected cytosol to delipidation by 
extraction with chloroform/methanol. The oligomerization ac- 
tivity was recovered in the pellet, which consisted mostly of 
proteins (not shown). To dissect this activity more precisely, 
the cytosol was subjected to a two phase chloroform/metha- 
nol/water extraction system. This system allows the partition 
of most lipids into the organic phase, of glycolipids and other 
amphiphilic ompounds into the aqueous phase and the con- 
centration of the precipitated proteins at the interface. As 
expected, no activity was found in the chloroform phase. Sur- 
prisingly, the protein containing fraction was inactive as well, 
whereas the aqueous phase was fully active (Fig. 1A). 
It is known that the aqueous phase among other amphi- 
philic compounds contains CoA derivatives [29]. Indeed, using 
reversed phased chromatography on a Smart system (Pharma- 
cia, Uppsala, Sweden) we detected significant amounts of 
acyl-CoA esters in the aqueous fraction (data not shown). 
We therefore investigated whether an acylation reaction 
could be involved in the oligomerization of VIP21-caveolin. 
This was tested by a mild alkaline methanolysis of the in vitro 
formed complexes. Incubation in the presence of methanolic 
KOH led to complete disruption of all types of oligomers, 
while no effect of methanol alone was observed (Fig. 1B, lanes 
1 and 2). This suggests that ester or thioester bonds may be 
required to retain the integrity of the complexes. Next, in the 
absence of cytosol, acyl-CoA esters were tested in the oligo- 
merization assay, as acylating agents. Their effect was indis- 
tinguishable from the effect of cytosol (Fig. 1C). Results, ex- 
pressed as the stimulation of oligomerization over the basal 
activity induced by HMKD buffer on the production of 400 
kDa complex, are shown in Fig. 1C. The various acyl-CoA 
esters, bearing saturated fatty acids (lauroyl-, myristoyl-, pal- 
mitoyl-, and stearoyl-CoA) tested at a concentration of 2 ~M, 
were equally efficient to induce the oligomer formation. No 
specificity linked to the length of a fatty acid was observed. 
To determine that the effect of acyl-CoA esters was not 
simply due to their detergent-like property, we used two re- 
agents with structures imilar to palmitoyl-CoA. Both palmi- 
toyl-carnitine (another amphiphilic ompound) and palmitoyl- 
dethio-CoA (a non-cleavable analogue of palmitoyl-CoA) 
were inactive in the oligomerization assay when tested at 
2 ~M (Fig. 1C). Palmitoyl-dethio-CoA did not act irreversi- 
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Fig. 1. Fatty acylation stimulates the in vitro oligomerization f VIP21-caveolin. A: The oligomerization assay was performed in the presence 
of buffer (lane 1), cytosol (lane 2) or different fractions of the chloroform/methanol extracted cytosol (aqueous phase, organic phase and inter- 
face, lanes 3-5 respectively). B: The oligomerization assay was performed in the presence of cytosol; the samples were treated either with 
methanol ( ane 1) or with 0.3 M KOH in methanol ( ane 2). C: The oligomerization assay was performed in the absence of cytosol, and in the 
presence of various compounds indicated at a concentration f 2/aM. The stimulation of the oligomerization above basal activity was measured 
in the 400 kDa complex. It is expressed as a ratio of radioactivity in 400 kDa in the presence of a tested compound to the radioactivity pro- 
duced by the incubation with buffer. C18-CoA, C16-CoA, C14-CoA, C12-CoA and Pal-deS-CoA are stearoyl-, palmitoyl-, myristoyl-, lauroyl- 
and palmitoyl-dethio-CoA, respectively. Pal-carnitine designates palmitoyl-carnitine. Molecular mass markers here or in subsequent figures are: 
rabbit muscle myosin (205 K), rabbit muscle phosphorylase b (97 K), bovine pancreas trypsinogen (24 K) and soybean trypsin inhibitor (20 K). 
bly, because 2 p.M palmitoyl-CoA added together with 0.2, 0.5 
and 1 I.tM of the non-cleavable analogue induced oligomeriza- 
tion (data not shown). A complete competition of 2 I.tM pal- 
mitoyl-CoA was achieved with 5 ~tM palmitoyl-dethio-CoA. 
Coenzyme A itself was also active in the post-translational 
assay, at the same concentration as palmitoyl-CoA. In con- 
trast, palmitic acid alone could not induce the complex for- 
mation. 
3.2. 25-Hydroxy-eholesterol can induce the formation of  the 
200 kDa complex 
Next, we assessed whether other lipids could substitute for 
acyl-CoA in this oligomerization process. We used 25-hydro- 
xy-cholesterol and sphingomyelin, instead of cytosol, in the 
post-translational assay. As shown in Fig. 2, incubation 
with 1 mg/ml 25-hydroxy-cholesterol led to the formation of 
the 200 kDa VIP21-caveolin complexes (lane 3). This process 
could not be inhibited by palmitoyl-dethio-CoA (lane 5). In 
contrast to the complexes generated in the presence of cytosol 
[21], the formation of the 200 kDa complexes induced by 25- 
hydroxy-cholesterol was not GTP dependent (Fig. 2, lanes 6 
and 7). Sphingomyelin had no effect at the concentrations 
tested (15-150 ~tM, data not shown). 
3.3. The oligomerization property of VIP21-caveolin is 
modified by eysteine residues 
The data above suggest hat lipid modification of a mole- 
cule involved in the oligomerization of VIP21-caveolin can 
influence that oligomerization process. As VIP21-caveolin 
was recently shown to be palmitoylated in vivo on three cy- 
steines present at the carboxy-terminal p rt of the protein [20], 
the simplest explanation of the above findings would be that 
palmitoylation of VIP21-caveolin influences its oligomeriza- 
tion. To provide further support for this hypothesis, we 
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decided to use the non-acylated Cys mutant lacking all three 
cysteine residues, as we have shown that this mutant is not 
palmitoylated [20]. For the in vitro oligomerization assay, in 
analogy to the TR VIP, a truncated form of the mutant (TR 
Cys-) utilizing the Met a2 initiation codon was produced. As 
shown in Fig. 3, the SDS resistant oligomerization of the 
cysteine deleted protein was almost completely abolished in 
comparison to the wild type VIP21-caveolin (cf. lanes 1 with 
3, 4, 5, and 6). It was only possible to observe a very small 
amount of the 400 kDa oligomers (< 5%) formed upon addi- 
tion of cytosol, 5 gM palmitoyl-CoA or CoA (lanes 8, 9 and 
10 respectively) by overexposing the autoradiographs, and no 
200 kDa oligomers were visible. 
We next examined whether the requirement for cysteine 
residues as acylation sites for oligomerization f VIP21-caveo- 
lin also held in vivo. The wild-type VIP21-caveolin and Cys- 
mutants were expressed by transfection i the human embryo- 
nic kidney 293 cell line [20]. As previously reported for en- 
dogenously expressed VIP21-caveolin i  MDCK cells [21], the 
transfected VIP21-caveolin formed SDS resistant, high mole- 
cular mass oligomers of approximately 200 and 400 kDa (Fig. 
4). In striking contrast, none of these oligomers were formed 
by the Cys- mutant, although it was expressed at approxi- 
mately equal protein levels. On extreme overexposure of the 
Western blot, a very small amount of 400 kDa oligomer was 
seen in some experiments (data not shown). Thus, the in vivo 
TRVIP 
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Fig. 2. 25-Hydroxy-cholesterol (25-OH-chol.) induces the formation 
of the 200 kDa complex. The oligomerization f TR VIP was per- 
formed in the absence of cytosol, and in the presence of the indi- 
cated compounds. 
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Fig. 3. SDS resistant oligomerization f VIP21-caveolin lacking all 
three cysteines i strongly impaired in vitro. The oligomerization f 
the truncated VIP21-caveolin (TR VIP, lane 1) or of the truncated 
mutant lacking all three cysteine residues (TR Cys-, lanes 2-11) 
was performed in the presence of the indicated compounds. C16- 
CoA and CoA were used at a concentration of 5 gM. 25-hydroxy- 
cholesterol at 1 mg/ml. 25-OH-chol. designates 25-hydroxy-cholester- 
ol. Lanes 7 11 show a longer exposure of lanes 2-6 (24 h and 90 
min, respectively). 
and in vitro data are in agreement and demonstrate he re- 
quirement for acylation of the cysteine residues in VIP21-ca- 
veolin for formation of SDS resistant oligomers of the pro- 
tein. 
The three cysteine residues in VIP21-caveolin are located at 
positions 133, 143, and 156, and all three sites are palmitoy- 
lated [20]. To ascertain if there was any differential influence 
of the individual cysteine residues on the oligomerization pro- 
cess, we expressed VIP21-caveolin mutants that had one or 
two of the cysteine residues mutated to serine, and analyzed 
cell lysates from transfected 293 cells for the presence of 
VIP21-caveolin oligomers. The single cysteine mutants (Fig. 
4) showed that the substitution of Cys aaa by Ser had no ap- 
parent effect on oligomerization, that Cys a4a was necessary for 
the formation of the 200 kDa oligomer (i.e. the Cys 14a to Ser 
mutant had almost exclusively the 400 kDa oligomers), and 
Cys ~6 was necessary for the formation of the 400 kDa oligo- 
mers. The double cysteine substitution mutants howed an 
oligomerization pattern that matched the added effects of 
the two single substitutions. Thus, substitution of Cys ~3a 
plus one of the other cysteine residues produced a similar 
pattern to that of the other cysteine residue alone, and the 
substitution of Cys 143 and Cys 156 completely abolished oligo- 
merization as assessed by SDS-PAGE (Fig. 4). 
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3.4. The effect of palmitoylation of VIP21-caveolin is to modify 
and stabilize oligomers that form independently of
acylation 
We next attempted to relate the above data showing an 
effect of palmitoylation on the oligomerization of VIP21-ca- 
veolin with other studies that indicate a clear role for peptide 
sequences in the oligomerization process. Specifically, we had 
earlier shown that complete removal of the amino-terminal 
cytoplasmic tail of VIP21-caveolin (amino acids 2-101) and 
replacement with sequences from human growth hormone led 
to loss of oligomerization [21]. Narrowing down the critical 
sequences further, we have found that deletion of amino acid 
residues 3-48 had no influence on oligomerization, but dele- 
tion of amino acids 46-95 completely abrogated oligomeriza- 
tion, as judged both by SDS-PAGE and by velocity sucrose 
gradient centrifugation i  the presence of octylglucoside (data 
not shown). These results are in agreement with a recently 
published study [22] which showed that a fusion protein con- 
taining amino acids 61-101 of VIP21-caveolin undergoes the 
same oligomerization as the intact VIP21-caveolin protein as 
judged by velocity sucrose gradient centrifugation performed 
in the presence of octylglucoside. Thus, these amino acids in 
the membrane proximal part of the amino-terminal cytoplas- 
mic tail appear necessary and sufficient for the oligomeriza- 
tion process. 
The question then arises as to why the Cys- mutant of 
VIP21-caveolin, which contains these amino acid residues 
61-101, did not appear to oligomerize by the SDS-PAGE 
.egg 
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Fig. 4. SDS resistant oligomerization pattern of VIP21-caveolin de- 
termined by specific ysteine residues. The oligomerization of var- 
ious VIP21-caveolin mutants containing zero, one, or two cysteine 
to serine substitutions was tested in transfected 293 cells. The cell 
lysates were analysed by SDS-PAGE separation of samples treated 
in SDS loading buffer at room temperature, followed by Western 
blot analysis for VIP21-caveolin. The various mutants are indicated 
above the lanes. The experiment has been repeated at least five 
times for each mutant, and this is a representative W stern blot. On 
this gel there is still some 200 kDa visible in the lane C133,143S but 
it is relatively depleted compared to the wild type or C133S. 
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Fig. 5. VIP21-caveolin mutant lacking all three cysteine residues 
forms oligomers that are disrupted by SDS. The wild type VIP21- 
caveolin and the Cys- mutant were expressed in 293 cells. A: Octyl- 
glucoside cell lysates were subjected to velocity sucrose gradient cen- 
trifugation and the fractions from the gradient were analyzed by 
SDS-PAGE under boiling conditions and analyzed by Western blot 
for DAF (as a 70 kDa marker protein), CavT and Cys-. B: Dupli- 
cate aliquots from fractions 8 and 9 from the gradient were ana- 
lyzed as above except he samples were not boiled before SDS- 
PAGE. 
assay (Figs. 3 and 4). To address this issue, we analyzed 293 
cells transfected with the wild-type or Cys- VIP21-caveolin 
for the presence of oligomers, using both the SDS-PAGE 
assay under non-boiling conditions and by velocity sucrose 
gradient centrifugation i  octylglucoside tergent. By the lat- 
ter assay, which involves milder non-ionic detergent condi- 
tions, the wild-type and Cys mutant VIP21-caveolin have 
formed the same size oligomers (Fig. 5A), both migrating to 
the bottom of the gradient (compare the migration to the 70 
kDa protein DAF which migrates much closer to the top of 
the gradient). However, when comparable fractions from the 
gradient are analyzed by SDS-PAGE under non-boiling con- 
ditions, only the oligomers from the wild-type VIP21-caveolin 
are observed, whereas those from the Cys- mutant have been 
completely broken up by exposure to 2% SDS and do not 
appear in the > 200 kDa region of the gel (Fig. 5B). Thus, 
the overall size of the oligomers (reflecting the number of 
molecules of VIP21-caveolin in the complex) is determined 
by the protein sequence (mapped to the amino-terminal cyto- 
plasmic tail), but palmitoylation of cysteine residues in the 
carboxy-terminal cytoplasmic tail leads to some modification 
of this oligomeric structure resulting in increased stability (as 
assessed by the detergent SDS). 
4. Discussion 
VIP21-caveolin is a component of the coat of caveolae [5]. 
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By immunoelectron microscopy, antibodies to VIP21-caveolin 
decorate the striated filaments on the cytoplasmic face of the 
caveolae [5]. The demonstration f oligomerization f VIP21- 
caveolin [21,22] elucidates part of the structure of this caveo- 
lar coat. In our opinion, to form the caveolar coat VIP21- 
caveolin must acquire two properties: it should become a part 
of a very high molecular mass complex (> 104 kDa), which 
contains cholesterol and glycosphingolipids and is insoluble in 
Triton [15,18]; this complex can resolve into high molecular 
mass oligomers (200-600 kDa) upon treatment with 2% SDS 
at room temperature [21,22]. In the present work we have 
investigated the contribution of different features of VIP21- 
caveolin, especially lipid modification, to the formation of the 
oligomers. The data support a complex model for oligomer- 
ization of the protein; peptide sequences in the membrane 
proximal region of the amino-terminal t il are necessary and 
sufficient for oligomerization f the protein [22], yet palmitoy- 
lation of cysteine residues in the carboxy-terminal cytoplasmic 
tail [20] leads to a modification of the oligomers that results in 
their resistance to disruption by 2% SDS at room tempera- 
ture. Both in vitro and in vivo, the stabilized oligomerization 
requires a form of VIP21-caveolin capable of being S-acy- 
lated. Although we still can not exclude that the oligomeriza- 
tion occurs due to the formation of S-S bridges upon solubi- 
lization, the fact that the SDS-PAGE solubilization buffer 
contained 2% I3ME (sometimes 100 mM DTT was used) 
and also dependence of in vitro oligomerization on GTP or 
Mg 2+ [21] speaks against unspecific oxidation of sulfhydryl 
groups. Fatty acyl CoA esters, as well as free CoA, produce 
the same effect in vitro as cytosol, and are likely to be the 
active components found in the cell extract. The fact that free 
CoA and all the tested CoA esters exhibit he same efficiency 
probably reflects the activity of acyl-CoA synthetases (thioki- 
nases) which are partially associated with the ER. The 
dependence of the in vitro oligomerization assay on ATP 
shown in our previous paper [21] can be explained by this 
activity. 
Our results give new insight into the link between caveolae 
(or VIP21-caveolin) and lipids, a link which had already been 
detected before, and consist of several observations. First, the 
addition of cholesterol binding drugs like filipin or nystatin 
changes the morphology of caveolae, making them flat [5,30]. 
Furthermore, the treatment of cells with cholesterol oxidase, 
an enzyme that produces cholestenon, leads to redistribution 
of VIP21-caveolin within the cell [31]. In our previous work, 
the 400 kDa homo-oligomer was prepared starting from Tri- 
ton X-114 insoluble floating fraction [21], which is enriched in 
glycosphingolipids as well as in cholesterol [27,32]. Moreover, 
as we recently showed, the 400 kDa complex contains choles- 
terol and VIP21-caveolin itself seems to be a cholesterol-bind- 
ing protein [28]. 
There are still several open questions concerning the role of 
palmitoylation i the structure and function of VIP21-caveo- 
lin and caveolae. We have shown that palmitoylation is not 
necessary for VIP21-caveolin to acquire Triton insolubility 
[20]. Moreover, electron microscopy studies show that the 
Cys- mutant of VIP21-caveolin is localized to caveolae in 
transfected 293 cells, indistinguishable from the wild-type pro- 
tein (R. Parton, D.M. Lublin and T.V. Kurzchalia, unpub- 
lished observations). Also, it is not clear how the palmitates 
modify the structure of VIP21-caveolin. All three of the cy- 
steine residues of the protein are located in the carboxy-ter- 
minal cytoplasmic tail of VIP21-caveolin and are palmitoy- 
lated [20]. Acylation should lead to attachment of the 
carboxy terminus to the membrane surface and thus the flat- 
tening of this domain of the polypeptide. It is possible that 
with the carboxy-terminal cytoplasmic tails flattened against 
the membrane, the amino-terminal cytoplasmic tails can inter- 
act more tightly with each other in forming an oligomer. 
Having elucidated the basic features of palmitoylation and 
oligomerization of VIP21-caveolin, the challenge now is to 
determine the role of these structural modifications in the 
function of VIP21-caveolin and caveolae. 
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